Osteoporosis
Conditions
Keywords
osteoporosis, BMD, teriparatide, bisphosphonate, denosmab
Brief summary
In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly divided following daily teriparatide in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.
Detailed description
Registry criteria: Patients treated in the investigators hospital using teriparatide. Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (\< young adult mean 65%). Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants
Interventions
None listed
Sponsors
Tomidahama Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* severe osteoporotic patients
Exclusion criteria
* cancer, hypercalcemia, etc (i.e. patients who could not use bisphosphonate, denosmab, teriparatide)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical results of bisphosphonate vs. denosmab following daily teriparatide treatment | Up to 36 months | The investigators plan to analyze 500 patients who treated with bisphosphonate or denosmab following daily teriparatide treatment. We investigate changes in BMD and bone turnover markers. |
Countries
Japan
Contacts
Primary ContactRui Niimi, MD, PhD
Outcome results
None listed